Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK39297 in Primary IgA Nephropathy
NCT06670352Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ciprocopan in IgA nephropathy (IgAN) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Ratio of 24-hour urine protein to creatinine compared to baseline at 12 weeks. Started Oct 2024; status: completed.
02
Drugs
ciprocopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06670352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670352.